Resveratrol inhibits prostate cancer growth and hormone resistance:An in vivo study
10.3969/j.issn.1006-5725.2025.12.009
- VernacularTitle:白藜芦醇抑制前列腺癌生长及激素抵抗的体内实验
- Author:
Hongchao SHAO
1
;
Qiyuan LUO
1
;
Wenbin GAO
1
;
Wen LUO
1
;
Mushi YE
1
Author Information
1. 广东医科大学附属医院泌尿外科(广东 湛江 524000)
- Publication Type:Journal Article
- Keywords:
resveratrol;
prostate cancer;
nudemice;
LNCaP cells;
LNCaP-B cells
- From:
The Journal of Practical Medicine
2025;41(12):1835-1839
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the inhibitory effects of resveratrol(Res)on the growth of hormone-dependent and castration-resistant prostate cancer(PCa)and explore its mechanisms.Methods Subcutaneous xenograft models were established in nude mice using the human prostate cancer cell lines LNCaP(hormone-sensitive)and its castration-resistant derivative LNCaP-B.Thirty nude mice were randomly divided into three groups:control group,Res-treated and docetaxel.Tumor growth was recorded.Quantitative real-time polymerase chain reaction(qRT-PCR)and Western blot were performed to assess androgen receptor(AR)mRNA and protein expression levels in tumor tissues.Results Moderate-and high-dose Res significantly inhibited the growth of both LNCaP and LNCaP-B xenografts in a dose-dependent manner,with statistical significance(P<0.05).qRT-PCR and Western blot analyses revealed that Res markedly downregulated AR mRNA expression and protein levels compared to the control group.However,no significant pathological alterations were observed in HE-stained tumor sections.Conclusions Resveratrol suppresses the growth of hormone-dependent and castration-resistant prostate cancer by inhibiting AR expression and signaling pathway activity.These findings highlight its potential as an adju-vant therapeutic agent to androgen deprivation therapy(ADT),providing a theoretical foundation for its clinical application in PCa treatment.
